Cerezyme is the ONLY ERT (enzyme replacement therapy) that has shown long-term efficacy and safety in multiple studies over 20 years and has been prescribed for over 25 years1-3
Cerezyme efficacy & safety studies overview
Cerezyme was proven to be safe and effective in 2 prospective clinical trials and was evaluated in multiple studies from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. The long-term safety of Cerezyme was shown in an international monitoring database.3-7
Explore the findings of 6 studies evaluating the safety and efficacy of Cerezyme in visceral, hematologic, and certain bone parameters in adult and pediatric populations with Gaucher disease type 1.1,3-7
Visceral &
Hematologic Data
|
Parameters assessed: Visceral and hematologic parameters |
|
20-Year, Long-Term Registry Study3,a Parameters assessed: Visceral, hematologic, bone pain, and bone crises |
Bone Data
|
48-Month, Long-Term Prospective Study4 Parameters assessed: Bone mineral density (BMD) and bone crises |
|
4-year, Long-Term Registry Study6 Parameters assessed: Bone pain and bone crises |
|
8-Year, Long-Term Registry Study5 Parameters assessed: BMD |
Pediatric Data
|
8-Year, Long-Term Registry Study7,a Parameters assessed: Visceral, hematologic, and BMD |
aThe Cerezyme treatment group from the ICGG Gaucher Registry analyses represents patients with Gaucher disease type 1 who received either alglucerase or imiglucerase.
The International Collaborative Gaucher Group (ICGG) Gaucher Registry
The ICGG Gaucher Registry is the world’s largest cooperative, observational database on Gaucher disease. The ICGG Gaucher Registry is sponsored by Sanofi and directed by the ICGG, a group of physicians who are experts in the management of Gaucher disease.8
- The ICGG Gaucher Registry provides observational data on more than 7000 patients with Gaucher disease worldwide3
Indication
References: 1. Cerezyme (imiglucerase). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. Am J Hematol. 2008;83(12):890-895. 3. Weinreb NJ, Camelo JS, Charrow J, et al. Mol Genet Metab. 2021;123(2):100-111. 4. Sims KB, Pastores GM, Weinreb NJ, et al. Clin Genet. 2008;73(5):430-440. 5. Wenstrup RJ, Kacena KA, Kaplan P, et al. J Bone Miner Res. 2007;22(1):119-126. 6. Charrow J, Dulisse B, Grabowski GA, Weinreb J. Clin Genet. 2007;71(3):205-211. 7. Andersson H, Kaplan P, Kacena K, Yee J. Pediatrics. 2008;122(6):1182-1190. 8. Weinreb NJ, Kaplan P. Am J Hematol. 2015;90(suppl 1):s2-s5.
